Linked Data API

Show Search Form

Search Results

1138979
registered interest false more like this
date less than 2019-07-15more like thismore than 2019-07-15
answering body
Church Commissioners more like this
answering dept id 9 more like this
answering dept short name Church Commissioners more like this
answering dept sort name Church Commissioners more like this
hansard heading Churches: Equality more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the right hon. Member for Meriden, representing the Church Commissioners, what discussions the (a) Church of England and (b) Church in Wales have had with (i) other religious and faith bodies, (ii) the Government and (iii) the Equality and Human Rights Commission on the exemption of those bodies from equality legislation for appointments and provision of services. more like this
tabling member constituency Gower remove filter
tabling member printed
Tonia Antoniazzi more like this
uin 277265 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2019-07-18
answer text <p>The Equality Act 2010 contains provisions that allow religious organisations to apply a limited range of religious occupational requirements to comply with the doctrines of the religion or to avoid conflicting with the strongly held religious beliefs of a significant number of the religion’s followers. The ability to apply religious occupational requirements arises where the employment is “for the purposes of an organised religion” and is not specific to the Church of England.</p><p>The Church of England has regular discussions with other religious and faith bodies, with HM Government, and with the Equality and Human Rights Commission on matters of mutual interest. From time to time these will include reflections on the importance for religious freedom of the provisions that protect faith and belief in the Equality Act.</p> more like this
answering member constituency Meriden more like this
answering member printed Dame Caroline Spelman more like this
question first answered
less than 2019-07-18T10:47:39.463Zmore like thismore than 2019-07-18T10:47:39.463Z
answering member
312
label Biography information for Dame Caroline Spelman more like this
previous answer version
129637
answering member constituency Meriden more like this
answering member printed Dame Caroline Spelman more like this
answering member
312
label Biography information for Dame Caroline Spelman more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this
1133166
registered interest false more like this
date less than 2019-06-19more like thismore than 2019-06-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision. more like this
tabling member constituency Gower remove filter
tabling member printed
Tonia Antoniazzi more like this
uin 266861 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-27more like thismore than 2019-06-27
answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-27T12:42:09.417Zmore like thismore than 2019-06-27T12:42:09.417Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this
1133167
registered interest false more like this
date less than 2019-06-19more like thismore than 2019-06-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products. more like this
tabling member constituency Gower remove filter
tabling member printed
Tonia Antoniazzi more like this
uin 266862 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-27more like thismore than 2019-06-27
answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-27T12:43:17.543Zmore like thismore than 2019-06-27T12:43:17.543Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this
1132764
registered interest false more like this
date less than 2019-06-18more like thismore than 2019-06-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text What progress the Government has made on making medical cannabis available to people who need it. more like this
tabling member constituency Gower remove filter
tabling member printed
Tonia Antoniazzi more like this
uin 911421 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-18more like thismore than 2019-06-18
answer text <p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.</p><p /><p /> more like this
answering member constituency West Suffolk more like this
answering member printed Matt Hancock more like this
question first answered
less than 2019-06-18T16:50:49.883Zmore like thismore than 2019-06-18T16:50:49.883Z
answering member
4070
label Biography information for Matt Hancock more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this